RxDoctor Payments Data

Randolph Senining, MD

Infectious Disease · Bakersfield, CANPI 1841216405

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 45 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$238
  • Astellas Pharma US Inc$212
  • Octapharma USA, Inc.$89
  • Amgen$78
  • GSK$51
  • AMAG Pharmaceuticals, Inc.$44
  • plus $364 from 15 others

What the payments were for

  • Food & beverage$90784%
  • Education$16916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,076 in reported general payments places this provider in the 60th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$386,786
Medicare patients
572
Services billed
4,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$54,467
BiktarvyBictegrav/Emtricit/Tenofov Ala11$45,744
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,564
Voriconazole18$23,353
VemlidyTenofovir Alafenamide12$16,492
Fluconazole68$10,869
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam31$7,595
Lamivudine-ZidovudineLamivudine/Zidovudine12$6,077
Meropenem35$5,304
Vancomycin Hcl22$3,345
Methenamine Hippurate36$1,852
Sodium Chloride0.9 % Sodium Chloride33$1,226
CeftriaxoneCeftriaxone Sodium11$790
Efavirenz11$768
Doxycycline Hyclate12$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$27$40,56411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 856 infectious disease providers in California.

Other infectious disease in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →